BioMarin Pharmaceutical Inc (BMRN):企業の財務・戦略的SWOT分析

◆英語タイトル:BioMarin Pharmaceutical Inc (BMRN) - Financial and Strategic SWOT Analysis Review
◆商品コード:GDPH27812FSA
◆発行会社(調査会社):GlobalData
◆発行日:2021年2月
◆ページ数:58
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:Pharmaceuticals and Healthcare
◆販売価格オプション(消費税別)
Site License(同一事業所内共有可)USD250 ⇒換算¥28,500見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD375 ⇒換算¥42,750見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

BioMarin Pharmaceutical Inc (BMRN) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

BioMarin Pharmaceutical Inc (BioMarin) is a biopharmaceutical company. It develops and commercializes innovative pharmaceuticals for treatment of serious diseases and medical conditions, such as Duchenne muscular dystrophy (DMD), phenylketonuria (PKU), achondroplasia, late infantile neuronal ceroid lipofuscinosis (CLN2) and hemophilia A. Its product category consists of multiple clinical and preclinical offerings which include Naglazyme-Mucopolysaccharidosis Type VI (MPS VI), Aldurazyme-MPS I and others. The company operates through its manufacturing facilities in Novato, California. It conducts its business operations in the US, Europe, Latin America, the Middle East and Asia-Pacific. BioMarin is headquartered in San Rafael, California, the US.

BioMarin Pharmaceutical Inc Key Recent Developments

Feb 18,2021: BioMarin Appoints Former Goldman Sachs Partner and Life Sciences Executive, Maykin Ho, Ph.D. to Board of Directors
Nov 05,2020: BioMarin announces third quarter 2020 total revenues of $477 million
Oct 05,2020: Scientific Luminary and MacArthur Fellowship winner, Kevin Eggan, Ph.D., joins BioMarin as Head of Research and Early Development
Sep 25,2020: Pomerantz law firm announces the filing of a class action against BioMarin Pharmaceuticals and certain officers – BMRN
Aug 04,2020: BioMarin announces second quarter 2020 total revenue growth of 11% to $430 million

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

【レポートの目次】

Table of Contents
List of Tables
List of Figures
Section 1 – About the Company
BioMarin Pharmaceutical Inc – Key Facts
BioMarin Pharmaceutical Inc – Key Employees
BioMarin Pharmaceutical Inc – Key Employee Biographies
BioMarin Pharmaceutical Inc – Major Products and Services
BioMarin Pharmaceutical Inc – History
BioMarin Pharmaceutical Inc – Company Statement
BioMarin Pharmaceutical Inc – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Joint Venture
Section 2 – Company Analysis
Company Overview
BioMarin Pharmaceutical Inc – Business Description
Product Category: Aldurazyme
Overview
Performance
Product Category: Brineura
Overview
Performance
Product Category: Firdapse
Overview
Performance
Product Category: Kuvan
Overview
Performance
Product Category: Naglazyme
Overview
Performance
Product Category: Palynziq
Overview
Performance
Product Category: Vimizim
Overview
Performance
Geographical Segment: Europe
Performance
Geographical Segment: Latin America
Performance
Geographical Segment: Rest of the World
Performance
Geographical Segment: United States
Performance
BioMarin Pharmaceutical Inc – Corporate Strategy
BioMarin Pharmaceutical Inc – SWOT Analysis
SWOT Analysis – Overview
BioMarin Pharmaceutical Inc – Strengths
BioMarin Pharmaceutical Inc – Weaknesses
BioMarin Pharmaceutical Inc – Opportunities
BioMarin Pharmaceutical Inc – Threats
BioMarin Pharmaceutical Inc – Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Performance Chart
Financial Performance
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
BioMarin Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
BioMarin Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
BioMarin Pharmaceutical Inc, Recent Deals Summary
Section 5 – Company’s Recent Developments
Feb 18, 2021: BioMarin Appoints Former Goldman Sachs Partner and Life Sciences Executive, Maykin Ho, Ph.D. to Board of Directors
Nov 05, 2020: BioMarin announces third quarter 2020 total revenues of $477 million
Oct 05, 2020: Scientific Luminary and MacArthur Fellowship winner, Kevin Eggan, Ph.D., joins BioMarin as Head of Research and Early Development
Sep 25, 2020: Pomerantz law firm announces the filing of a class action against BioMarin Pharmaceuticals and certain officers – BMRN
Aug 04, 2020: BioMarin announces second quarter 2020 total revenue growth of 11% to $430 million
Jul 02, 2020: BioMarin Pharmaceutical: Departure of directors or certain officers; election of directors; appointment of certain officers; compensatory arrangements of certain officers
Jun 29, 2020: BioMarin Promotes Company Veteran, Brian R. Mueller, to executive vice president, CFO
May 11, 2020: BioMarin announces proposed private offering of $500 Million of senior subordinated convertible notes
May 03, 2020: BioMarin extends Gene Therapy leadership with DiNAQOR in a preclinical collaboration and license agreement to develop Gene Therapies for Rare Genetic Cardiomyopathies
Apr 29, 2020: BioMarin announces first quarter 2020 total revenue growth of 25% to $502 million
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List of Tables
BioMarin Pharmaceutical Inc, Key Facts
BioMarin Pharmaceutical Inc, Key Employees
BioMarin Pharmaceutical Inc, Key Employee Biographies
BioMarin Pharmaceutical Inc, Major Products and Services
BioMarin Pharmaceutical Inc, History
BioMarin Pharmaceutical Inc, Subsidiaries
BioMarin Pharmaceutical Inc, Joint Venture
BioMarin Pharmaceutical Inc, Key Competitors
BioMarin Pharmaceutical Inc, Ratios based on current share price
BioMarin Pharmaceutical Inc, Annual Ratios
BioMarin Pharmaceutical Inc, Annual Ratios (Cont...1)
BioMarin Pharmaceutical Inc, Interim Ratios
BioMarin Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
BioMarin Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
BioMarin Pharmaceutical Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

★海外企業調査レポート[BioMarin Pharmaceutical Inc (BMRN):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • genOway SA (ALGEN):製薬・医療:M&Aディール及び事業提携情報
    Summary genOway SA (genOway) is a biotechnology company that develops genetically modified mouse, rat and cellular models for pharmaceutical companies and research institutes. The company develops several technology platforms such as safe DNA transgenesis, quick knock-in, safe in vivo RNAi and safe …
  • Solent NHS Trust:企業の戦略的SWOT分析
    Solent NHS Trust - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servi …
  • Frasers Property Limited:企業の戦略・SWOT・財務情報
    Frasers Property Limited - Strategy, SWOT and Corporate Finance Report Summary Frasers Property Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • BGFIBank Group:企業の戦略・SWOT・財務分析
    BGFIBank Group - Strategy, SWOT and Corporate Finance Report Summary BGFIBank Group - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • Kohl’s Corp (KSS):企業の財務・戦略的SWOT分析
    Kohl's Corp (KSS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Nippon Yusen Kabushiki Kaisha:企業の戦略・SWOT・財務分析
    Nippon Yusen Kabushiki Kaisha - Strategy, SWOT and Corporate Finance Report Summary Nippon Yusen Kabushiki Kaisha - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • TOWER Limited:企業の戦略・SWOT・財務分析
    TOWER Limited - Strategy, SWOT and Corporate Finance Report Summary TOWER Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Sekisui House, Ltd.:企業の戦略・SWOT・財務分析
    Sekisui House, Ltd. - Strategy, SWOT and Corporate Finance Report Summary Sekisui House, Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • St. George’s University of London-製薬・医療分野:企業M&A・提携分析
    Summary St. George's University of London (SGUL), a subsidiary of University of London is a medical and healthcare education provider that offers undergraduate and post graduate courses. The university’s undergraduate courses include biomedical science BSc, healthcare practice DipHE and BSc, healthc …
  • ADOBE Inc (ADBE):企業の財務・戦略的SWOT分析
    ADOBE Inc (ADBE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Centers for Disease Control and Prevention-製薬・医療分野:企業M&A・提携分析
    Summary Centers for Disease Control and Prevention (CDC), a subsidiary of US Department of Health and Human Services is a public health institute that offers health, safety and security threat management solutions. The institute provides health information to fight diseases and support communities f …
  • Prestige Brands Holdings Inc (PBH):製薬・医療:M&Aディール及び事業提携情報
    Summary Prestige Brands Holdings Inc (Prestige) focuses on the marketing, sales and distribution of over-the-counter (OTC) healthcare and household cleaning brands. The company offers its products for digestive care; lice treatment, household cleaning; hygiene; oral care; pain relief; pediatric care …
  • Caixa Economica Montepio Geral:企業の戦略・SWOT・財務分析
    Caixa Economica Montepio Geral - Strategy, SWOT and Corporate Finance Report Summary Caixa Economica Montepio Geral - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Aragen Bioscience Inc-製薬・医療分野:企業M&A・提携分析
    Summary Aragen Bioscience Inc (Aragen), a subsidiary of GVK Biosciences Inc is a contract research organisation that provides preclinical contract research and development services. The company provides recombinant cell line and hybridoma development, cell culture and protein purification process de …
  • China Gas Holdings Ltd (384):企業の財務・戦略的SWOT分析
    China Gas Holdings Ltd (384) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • Repsol Sinopec Resources UK Ltd:石油・ガス:M&Aディール及び事業提携情報
    Summary Repsol Sinopec Resources UK Ltd (Repsol Sinopec), formerly Talisman Sinopec Energy UK Ltd is an oil and gas company that offers exploration services. The company explores, discovers, and produces oil and gas across the North Sea. It provides operation in floating facilities, offshore platfor …
  • Joint Stock Company Russian Agricultural Bank:企業の戦略・SWOT・財務分析
    Joint Stock Company Russian Agricultural Bank - Strategy, SWOT and Corporate Finance Report Summary Joint Stock Company Russian Agricultural Bank - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, opera …
  • Bunge North America Inc:企業の戦略・SWOT・財務情報
    Bunge North America Inc - Strategy, SWOT and Corporate Finance Report Summary Bunge North America Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Good Energy Group PLC (GOOD):電力:M&Aディール及び事業提携情報
    Summary Good Energy Group PLC (Good Energy) is a vertically integrated energy utility. It supplies renewable electricity and gas; provides feed in tariff services; and procures electricity from renewable energy generators. The company serves as an integrator of green energy and technical services. G …
  • Australian Gas Networks Ltd:電力:M&Aディール及び事業提携情報
    Summary Australian Gas Networks Ltd (Australian Gas Networks), formerly Envestra Ltd is an oil and gas company that distributes and transports natural gas. The company's services include managing the haulage of gas through each network, operation and maintenance of gas network, design an constructio …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆